Abstract
Drug development expenditures continue to escalate, in part reflecting inefficiencies in current drug discovery paradigms. Traditional drug discovery has been dichotomous, focusing either on phenotypic effects of distinct agents in biological systems, without knowledge of respective targets, or on target-based activities of specific molecules in cell-free assays. Driven by advances in biology, engineering, and informatics, new paradigms integrate phenotypic with target-based algorithms into comprehensive, systems-level approaches offering value-added strategies for optimized drug discovery.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
